A Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
Phase of Trial: Phase IV
Latest Information Update: 10 Jul 2019
Price : $35 *
At a glance
- Drugs Brodalumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 09 May 2019 Results published in the Journal of the American Academy of Dermatology
- 21 Dec 2018 Status changed from active, no longer recruiting to completed.
- 12 Sep 2018 Planned End Date changed from 30 Jun 2018 to 30 Oct 2018.